MYRIAD GENETICS INC
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for
Condensed Consolidated Statements of Cash Flows (unaudited)
| Three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(34.1) | $(0.1) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 12.5 | 14.4 |
| Non-cash lease expense | 1.0 | 2.8 |
| Stock-based compensation expense | 6.5 | 9.5 |
| Unrecognized tax benefits | — | (31.3) |
| Impairment of goodwill and long-lived assets | 5.4 | — |
| Other non-cash adjustments | 1.2 | 0.5 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (9.7) | (2.2) |
| Trade accounts receivable | (8.7) | 0.8 |
| Inventory | 2.7 | (0.9) |
| Prepaid taxes | 10.0 | 2.1 |
| Other assets | (0.5) | 0.5 |
| Accounts payable | 5.4 | — |
| Accrued liabilities | (7.4) | (12.4) |
| Net cash used in operating activities | (15.7) | (16.3) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures | (5.4) | (5.3) |
| Capitalization of intangible assets | (1.1) | (3.0) |
| Net cash used in investing activities | (6.5) | (8.3) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Payment of tax withheld for common stock issued under stock-based compensation plans | (2.9) | (5.8) |
| Proceeds from revolving credit facility | — | 40.0 |
| Repayment of revolving credit facility | — | (20.5) |
| Payment on finance leases | (0.1) | (0.1) |
| Net cash (used in) provided by financing activities | (3.0) | 13.6 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | (0.1) | 0.1 |
| Net decrease in cash, cash equivalents, and restricted cash | (25.3) | (10.9) |
| Cash, cash equivalents, and restricted cash at beginning of the period | 151.3 | 111.9 |
| Cash, cash equivalents, and restricted cash at end of the period | $126.0 | $101.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.